• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Amphetamines and Topiramate for Cocaine Use Disorder

Amphetamines and Topiramate for Cocaine Use Disorder

June 10, 2020
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD. Dr Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Levin FR et al, Drug Alcohol Depend 2020;206:107700

In 2017, an estimated 2.2 million Americans used cocaine, with about 966,000 of them meeting criteria for cocaine use disorder (CUD) (SAMHSA, 2018). Unfortunately, there are still no FDA-approved treatments for CUD. Amphetamines increase synaptic dopamine transmission and may therefore reduce the reinforcing properties of cocaine. Topiramate, an anticonvulsant that enhances gamma amino butyric acid (GABA) activity, can reduce cocaine-induced dopamine release and may modulate the reinforcing effects of co-administered amphetamines. Previously, a single-site study suggested that a combination of amphetamine and topiramate can reduce cocaine use in individuals with high baseline cocaine consumption (Mariani JJ et al, Biol Psychiatry 2012;72(11):950–956). Now, researchers have conducted a larger trial with the same combination, among people who use cocaine, across two large metropolitan areas.

This trial tested the combination of mixed amphetamine salts extended-release (MAS-ER) and topiramate vs placebo in double-blinded, randomized design. The study was conducted over a 12-week period and included 127 adults (96 men, ages 18–60) with CUD. Participants reported using cocaine for at least 9 days in the previous month. MAS-ER was titrated to a maximum dose of 60 mg/day, and topiramate was increased to a maximum dose of 100 mg twice/day. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence, as measured by urine toxicology and self-report. Funding was provided by the National Institute on Drug Abuse.

The proportion of participants achieving 3 weeks of abstinence was significantly larger in the treatment compared to the placebo group (14.1% vs 0.0%, p = 0.03) after controlling for other factors. Secondary analyses showed that the proportion of participants who achieved any 3 consecutive weeks of abstinence (but not necessarily end-of-study abstinence) was higher for those receiving MAS-ER and topiramate (21.9%) compared to placebo (6.3%). Cocaine cravings also were significantly less prevalent among the treatment group (p < 0.001). Dropouts were high in both study arms (34% in the treatment group, 41% in the placebo group). Dry mouth was the only adverse event significantly more common in the treatment group than the placebo arm (16% vs 5%). Among those receiving MAS-ER and topiramate, 20.3% were discontinued from the medications due to increased blood pressure and heart rate.

CATR’s Take
The combination of amphetamine and topiramate can increase abstinence and decrease cravings among those with CUD. However, cardiovascular side effects limit widespread use, and it remains unclear whether the combination of MAS-ER and topiramate outperforms either medication alone.
Addiction Treatment
KEYWORDS cocaine pharmacology research research-update
Rehan Aziz, MD.

Mood Stabilizers for Bipolar Disorder in Older Adults: Special Considerations

More from this author
www.thecarlatreport.com
Issue Date: June 10, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Emerging Risks for Old Medications, CATR, May/June 2020
Gabapentin for Alcohol Use Disorder, Redux
Does Baclofen Titrated to High Doses Reduce Alcohol Use?
Amphetamines and Topiramate for Cocaine Use Disorder
E-Cigarettes vs Nicotine Replacement for Smoking Cessation
Benzodiazepines: Old Medicines, New Concerns
Muscle Relaxants: Sedatives Often Under the Radar
SAMHSA Relaxes Regulations on Methadone and Buprenorphine During COVID-19 Emergency
Gabapentin Misuse and Diversion
The “Z-Drugs”: Safety Issues and Misuse Potential
Note From the Editor-in-Chief
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.